Volume 4, Issue 6, Pages (December 2001)

Slides:

Advertisements

Similar presentations

Cell Physiol Biochem 2013;32: DOI: /

Advertisements

Molecular Therapy - Oncolytics

Volume 10, Issue 2, Pages (August 2004)

An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis Li-Wen Liu, Tomoyuki Nishikawa,

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression.

Christine M. Braun, BA, Shau-Ku Huang, PhD, Gregory G

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Volume 119, Issue 4, Pages (October 2000)

Volume 25, Issue 3, Pages (March 2017)

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

CpG Methylation of a Plasmid Vector Results in Extended Transgene Product Expression by Circumventing Induction of Immune Responses A. Reyes-Sandoval,

Lineage-Restricted Expression of Protein Kinase C Isoforms in Hematopoiesis by Alessandra Bassini, Giorgio Zauli, Giovanni Migliaccio, Anna Rita Migliaccio,

Mohan Babu Appaiahgari, Sudhanshu Vrati Molecular Therapy

Inhibition of Murine Cytomegalovirus Infection in Animals by RNase P-Associated External Guide Sequences Wei Li, Jingxue Sheng, Mengqiong Xu, Gia-Phong.

Volume 10, Issue 6, Pages (December 2004)

Complete Cure of Persistent Virus Infections by Antiviral siRNAs

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses William H.D. Hallett, Erik Ames, Maite.

Volume 13, Issue 1, Pages (January 2006)

Volume 10, Issue 6, Pages (December 2004)

DIO2 modifies inflammatory responses in chondrocytes

Jin-Sung Chung, Kyoichi Tamura, Ponciano D. Cruz, Kiyoshi Ariizumi

Volume 7, Issue 2, Pages (February 2003)

Volume 16, Issue 12, Pages (December 2008)

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

Volume 3, Issue 2, Pages (February 2001)

The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine Jay E. Slater, MDa, Elizabeth.

Volume 3, Issue 5, Pages (May 2001)

Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity Xinping Fu, Armando Rivera, Lihua.

Volume 9, Issue 6, Pages (June 2004)

Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.

Volume 13, Issue 2, Pages (February 2006)

Volume 2, Issue 4, Pages (October 2000)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell

Volume 12, Issue 5, Pages (November 2005)

Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node Lifang Cheng,

CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.

Volume 3, Issue 1, Pages (January 2001)

Volume 12, Issue 5, Pages (November 2005)

Thomas S. Griffith, Elizabeth L. Broghammer Molecular Therapy

Yoav Peretz, Zheng Frank Zhou, Fawaz Halwani, Gérald J. Prud'homme

Volume 22, Issue 1, Pages (January 2014)

Volume 20, Issue 5, Pages (May 2012)

Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley Molecular Therapy

Ajay Gautam, Charles L. Densmore, J.Clifford Waldrep Molecular Therapy

Volume 8, Issue 2, Pages (August 2003)

Volume 18, Issue 5, Pages (May 2010)

Volume 8, Issue 1, Pages (July 2003)

Molecular Therapy - Oncolytics

Volume 4, Issue 6, Pages (December 2001)

Volume 26, Issue 1, Pages (January 2018)

Volume 3, Issue 6, Pages (June 2001)

Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand Yelena Glinka,

Inhibition of Murine Cytomegalovirus Infection in Animals by RNase P-Associated External Guide Sequences Wei Li, Jingxue Sheng, Mengqiong Xu, Gia-Phong.

Volume 20, Issue 3, Pages (March 2012)

Volume 9, Issue 3, Pages (March 2004)

Volume 8, Issue 2, Pages (August 2003)

Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters Kenji.

Volume 4, Issue 4, Pages (October 2001)

Volume 20, Issue 6, Pages (June 2012)

Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer

Molecular Therapy - Nucleic Acids

Genetic Targeting of the Active Transcription Factor XBP1s to Dendritic Cells Potentiates Vaccine-induced Prophylactic and Therapeutic Antitumor Immunity

Systemic Administration of Platelets Incorporating Inactivated Sendai Virus Eradicates Melanoma in Mice Tomoyuki Nishikawa, Li Yu Tung, Yasufumi Kaneda

Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating Factor

Volume 3, Issue 5, Pages (May 2001)

Volume 18, Issue 10, Pages (October 2010)

Volume 12, Issue 5, Pages (November 2005)

Volume 13, Issue 21, Pages (October 2003)

Presentation transcript:

Volume 4, Issue 6, Pages 551-558 (December 2001) Gene Therapy for Head and Neck Cancer Using Vaccinia Virus Expressing IL-2 in a Murine Model, with Evidence of Immune Suppression Hongxing Qin, Joseph Valentino, Subha Manna, Pulak K. Tripathi, Malaya Bhattacharya-Chatterjee, Kenneth A. Foon, Bert W. O'Malley, Sunil K. Chatterjee Molecular Therapy Volume 4, Issue 6, Pages 551-558 (December 2001) DOI: 10.1006/mthe.2001.0493 Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 1 In vivo expression of rvv-IL-2. The number of viral particles (pfu) and the amounts of IL-2 secreted in the tumors following intratumoral injection of rvv-IL-2 were determined. Each point in the graph represents the mean value obtained from three mice. Molecular Therapy 2001 4, 551-558DOI: (10.1006/mthe.2001.0493) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 2 Survival of mice with oral SCC VII tumors. Each group consisted of 10 mice. Molecular Therapy 2001 4, 551-558DOI: (10.1006/mthe.2001.0493) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 3 Proliferation of T cells by ConA. Proliferation of spleen, bone marrow or lymph node cells from normal mice (none), mice bearing oral SCC tumors (neck), or subcutaneous SCC tumors (skin) in the presence of ConA was determined. Radioactivity in the absence of ConA was subtracted from the corresponding values. Each group had three mice and the proliferation assay was performed separately for each mouse. Mean and SD of counts in each group are shown. Molecular Therapy 2001 4, 551-558DOI: (10.1006/mthe.2001.0493) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 4 Immune suppression in mice bearing SCC tumors on various days after tumor implantation. Proliferation of spleen cells in the presence of ConA was performed as described in Materials and Methods. Inhibition of the stimulation is expressed as a percentage of the stimulation by ConA of splenocytes from age-matched mice without tumors. Each point in the graph represents the mean value obtained from three mice. Molecular Therapy 2001 4, 551-558DOI: (10.1006/mthe.2001.0493) Copyright © 2001 American Society for Gene Therapy Terms and Conditions

FIG. 5 Shotgun identification of suppressor molecules involved in immune modulation. RT-PCR products were analyzed by agarose gel electrophoresis (A). The amplified DNA was transferred to nitrocellulose paper and Southern blot (B) was performed using specific oligonucleotides labeled by γ-[P32]ATP. Lane 1, RNA from tumor lesion; lane 2, RNA from cultured cells. Molecular Therapy 2001 4, 551-558DOI: (10.1006/mthe.2001.0493) Copyright © 2001 American Society for Gene Therapy Terms and Conditions